tiprankstipranks

Checkpoint Therapeutics price target lowered to $20 from $34 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Checkpoint Therapeutics to $20 from $34 and keeps a Buy rating on the shares following the Q2 report. The analyst cites dilution from recent equity raises for the target drop. The firm remains confident that cosibelimab “has a very strong chance” of approval, moving into commercialization stages, and should be added to the market soon after.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue